Objective To explore the effect of proximal femoral nail antirotation (PFNA) on treatment of elderly patients with intertrochanteric fractures.Methods A total of 90 elderly patients with intertrochanteric fractures were selected as observation group,and they were treated with PFNA.A total of 70 elderly patients with intertrochanteric fractures by treatment of dynamic hip screw were selected as control group.Surgical effect was compared between two groups.Results Compared with the control group,operation time,hospitalization time,full weight-bearing time and blood loss in the observation group were significantly better (P ＜ 0.05).There were no significant differences in excellent rate and postoperative complications between two groups (P ＞ 0.05).Conclusion PFNA has advantages such as short operation time and less blood loss in the treatment of elderly patients with intertrochanteric fractures.

Objective To explore the effect of proximal femoral nail antirotation (PFNA) on treatment of elderly patients with intertrochanteric fractures.Methods A total of 90 elderly patients with intertrochanteric fractures were selected as observation group,and they were treated with PFNA.A total of 70 elderly patients with intertrochanteric fractures by treatment of dynamic hip screw were selected as control group.Surgical effect was compared between two groups.Results Compared with the control group,operation time,hospitalization time,full weight-bearing time and blood loss in the observation group were significantly better (P ＜ 0.05).There were no significant differences in excellent rate and postoperative complications between two groups (P ＞ 0.05).Conclusion PFNA has advantages such as short operation time and less blood loss in the treatment of elderly patients with intertrochanteric fractures.

As a representative chemotherapeutic drug, docetaxel (DTX) has been used for breast cancer treatment for decades. However, the poor solubility of DTX limits its efficacy, and the DTX based therapy increases the metastasis risk due to the upregulation of C-X-C chemokine receptor type 4 (CXCR4) expression during the treatment. Herein, we conjugated CXCR4 antagonist peptide (CTCE) with DTX (termed CTCE-DTX) as an anti-metastasis agent to treat breast cancer. CTCE-DTX could self-assemble to nanoparticles, targeting CXCR4-upregulated metastatic tumor cells and enhancing the DTX efficacy. Thus, the CTCE-DTX NPs achieved promising efficacy on inhibiting both bone-specific metastasis and lung metastasis of triple-negative breast cancer. Our work provided a rational strategy on designing peptide-drug conjugates with synergistic anti-tumor efficacy.